04 January 2016
Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled on Monday with the SEC to raise up to $86 million in an initial public offering.
The company originally set terms in June 2014 to raise $60 million, but withdrew its offering.
The Waltham, MA-based company was founded in 2005 and plans to list on the Nasdaq under the symbol SNDX. Syndax Pharmaceuticals filed confidentially on August 25, 2015. Morgan Stanley and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024